Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (vi) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms (such as for NKTR-102), our business, results of operations and financial condition could suffer; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC on July 28, 2010, the Current Report on Form 8-K filed with the SEC today, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 to be filed with the SEC on or about November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(650) 631-4954Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-866
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... YORK , Feb. 27, 2015 /PRNewswire/ ... are increasing in applications as their effectiveness ... firm Kalorama Information.  Kalorama Information says that ... is the most powerful tool in proteomic ... spec; MS) through its traditional techniques has ...
(Date:2/26/2015)... CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ ... that 15 abstracts of studies in its neuroscience ... presentation during the 67 th American Academy ... D.C. , from April 18-25. The accepted ... product, DUOPA, in addition to investigational treatments in ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... Solar Cells, Inc. (OTCBB: PVSO) ("PhotoVoltaic" or the ... it completed a share exchange with MetaStat, Inc. ... and commercializing proprietary clinical diagnostic tests that predict ... companion therapeutics to prevent systemic metastasis.  In connection ...
... Feb. 28, 2012 Organovo, Inc. (OTCQB: ONVO) has been ... Review ,s annual list of the world,s most innovative ... are nominated by Technology Review ,s editors, who look ... and valuable technology, are bringing that technology to market at ...
Cached Medicine Technology:PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 3PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 4Organovo Named to MIT Technology Review's 2012 TR50 List of the World's Most Innovative Companies 2Organovo Named to MIT Technology Review's 2012 TR50 List of the World's Most Innovative Companies 3
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
(Date:2/28/2015)... 28, 2015 The Mesothelioma Applied ... awards at the International Symposium on Malignant Mesothelioma on ... at the Hyatt Regency Bethesda in Bethesda, Maryland. The ... work and commitment to the mission to cure mesothelioma. ... will be presented to Miriam Ratner. Miriam runs the ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
(Date:2/28/2015)... Orlando, FL (PRWEB) February 28, 2015 ... community organization has sponsored visitor health insurance programs for ... 25 years. Most Indian elderly parents traveling to the ... conditions such as diabetes and blood pressure. These diseases ... do not even list them as medical conditions. There ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... Avastin, researchers say , , WEDNESDAY, March 12 (HealthDay News) -- ... by doing what it,s supposed to -- but in the ... is bevacizumab, is the first member of a family of ... supply. It does this by inhibiting the action of vascular ...
... nodes could alter treatment approach, study suggests , , WEDNESDAY, ... tumors and tissue from patients with early-stage lung cancer ... say researchers at the Johns Hopkins Kimmel Cancer Center. ... approach for lung cancers, which recur within five years ...
... Public Understanding of a,21st Century Epidemic, ... of the,population, experts warn that Alzheimer,s disease ... and unsustainable burdens in,terms of health care ... lost to a devastating disease., (Photo: ...
... March 12 Omega Protein Corporation,(NYSE: OME ), ... fish meal products, today reported net income of $12.1 ... 31, 2007, compared with,net income of $4.6 million ($0.19 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO ), For the year ended ...
... Calif., March 12 Race Central, the country,s,preeminent ... annual Vigor Latino 5K run/walk ( http://www.VigorLatino5K.com ) ... California on Saturday, March,29, 2008. The Vigor Latino ... a special opportunity to take part in a ...
... HA Concepts Inc. introduces Conquer Omega T, an Omega 3 and Turmeric ... ... HA Concepts, Inc., the makers,of Conquer HA(TM), introduce the latest addition ... http://www.conquerha.com . Conquer Omega T,is powerful natural anti-inflammatory formula containing Omega ...
Cached Medicine News:Health News:Doctors See How Cancer Drug Can Damage Kidneys 2Health News:Doctors See How Cancer Drug Can Damage Kidneys 3Health News:Genetic Markers May Predict Lung Cancer Recurrence 2Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Omega Protein Reports 2007 Results 2Health News:Omega Protein Reports 2007 Results 3Health News:Omega Protein Reports 2007 Results 4Health News:Omega Protein Reports 2007 Results 5Health News:Race Central Launches Vigor Latino 5K Run/Walk, Promoting Hispanic Health, Fun and Fitness 2Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2
Functional trainer...
... Lipoprint HDL System separates HDL into large, ... values for each subfraction. The test procedure ... less than three hours. A color coded ... is clearly seen., ,The Lipoprint HDL Kit ...
... This control is designed to validate ... and apolipoprotein testing methods. This control is ... Series, Cobas, Dimension, Hitachi, Synchron and Vitros. ... methods and HDL precipitation methods: Dextran Sulfate ...
... use with Leica Unistat and ... and all automated bilirubin methods ... AU Series, Cobas, Dimension, Hitachi, ... contain purified bilirubin in a ...
Medicine Products: